Gynazole-1 Shortage: What Providers and Prescribers Need to Know in 2026

Gynazole-1 (butoconazole nitrate 2% vaginal cream) continues to present availability challenges for patients in 2026. While no formal FDA shortage is in effect, prescribers are increasingly hearing from patients who cannot locate this medication at their local pharmacy. This article outlines the clinical context of these challenges, summarizes evidence-based alternatives, and offers practical guidance for supporting affected patients.

The Current Availability Landscape

Gynazole-1 is not on the FDA Drug Shortages Database as of 2026. However, it is a brand-name-only product with no FDA-approved generic equivalent, manufactured solely by Padagis. Pharmacy pricing data identifies it as "less popular than comparable drugs," which directly translates to inconsistent stocking patterns. Many pharmacies — including large chains — do not carry it routinely.

The practical result: patients with a valid prescription for Gynazole-1 may need to visit or call multiple pharmacies before locating one with it in stock. This is a particularly significant issue for patients in rural areas, patients with mobility limitations, and those who need treatment quickly.

Why This Happens: The Structural Issues

Several intersecting factors contribute to Gynazole-1's limited pharmacy availability:

• Single-source manufacturing. With only one manufacturer and one product form (single-dose prefilled applicator), there is no buffer against supply disruptions or shifts in demand.
• High retail price. At $165–$169 retail per single-dose applicator, without insurance Gynazole-1 is priced significantly higher than OTC alternatives. Insurance coverage is inconsistent — some plans cover it, but Medicare typically does not.
• Competition from OTC options. Miconazole, clotrimazole, and tioconazole are all available OTC, reducing the prescription market for agents like Gynazole-1 and further diminishing pharmacy incentives to stock it.

Clinical Considerations: When Is Gynazole-1 Specifically Indicated?

Gynazole-1 is FDA-approved for the local treatment of vulvovaginal candidiasis caused by Candida. It is indicated for non-pregnant women and offers the clinical advantage of single-dose treatment, which may improve adherence in patients with complex medication schedules or who have difficulty completing multi-day regimens.

Important prescribing notes:

• Safety and effectiveness in pregnant women has not been established — use only when potential benefit justifies potential risk
• The cream contains mineral oil, which can weaken latex condoms and diaphragms for up to 72 hours post-treatment — counsel patients accordingly
• Recurrent VVC that is difficult to eradicate can be an early indicator of HIV in at-risk women
• Diagnosis should be confirmed by KOH smears and/or cultures, not clinical symptoms alone

Evidence-Based Alternatives to Consider

The CDC's STI Treatment Guidelines (2021, updated) include multiple first-line alternatives for uncomplicated VVC:

OTC intravaginal agents (first-line for uncomplicated VVC):

• Miconazole 2% cream 5g intravaginally daily for 7 days; or 4% cream 5g for 3 days; or 1,200 mg vaginal suppository for 1 day
• Clotrimazole 2% cream 5g intravaginally daily for 3 days
• Tioconazole 6.5% ointment 5g intravaginally as single application

Prescription intravaginal agents:

• Terconazole 0.4% cream 5g daily for 7 days; or 0.8% cream 5g for 3 days; or 80 mg suppository for 3 days (generic available)

Oral option:

• Fluconazole 150 mg orally as single dose (widely available generic; avoid in pregnancy and in women with hepatic impairment or taking medications with known CYP2C9/CYP3A4 interactions)

Practical Prescribing Strategies

Given ongoing Gynazole-1 availability challenges, consider these strategies:

1. Write a therapeutic substitution note. When prescribing Gynazole-1, note on the script or in your EHR that terconazole or fluconazole is an acceptable substitute if Gynazole-1 is not available at the dispensing pharmacy.
2. Counsel patients about the savings program. Padagis offers the Gynazole-1 Patient Savings Program (gynazole.com) that can reduce the cost to as low as $25 for commercially insured patients. This may help more patients afford to fill the prescription when they find it.
3. Refer patients to medfinder. medfinder.com/providers offers a provider-facing service that helps patients locate medications in stock at nearby pharmacies. Recommending this service to patients can reduce your office's callback volume from patients unable to fill their prescriptions.

Bottom Line for Providers

Gynazole-1 has no active FDA shortage in 2026, but its limited pharmacy stocking continues to cause real disruptions for patients. Proactive prescribing strategies — including therapeutic substitution authorization and directing patients to resources like medfinder — can help minimize patient frustration and treatment delays while maintaining evidence-based clinical care.